Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20176050 | 0.89 | CYP2D6 (0.34) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL20176052 | 0.85 | KDM4E (0.31) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL20176044 | 0.77 | ALDH1A1 (0.36) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL20176041 | 0.77 | CYP2D6 (0.35) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL20176042 | 0.75 | CYP2D6 (0.33) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL20176043 | 0.73 | CYP2D6 (0.37) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL20176054 | 0.72 | CYP2D6 (0.33) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL31285971 | 0.72 | CYP2C19 (0.34) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL20176045 | 0.70 | KCNN4 (0.43) | OPRM1RAB9A | |
| SCHEMBL20176070 | 0.69 | SLC6A2 (0.37) | CYP2D6CYP3A4ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450331-B2 | Functionalized cyanosilane and synthesis method and use thereof | EAST CHINA NORMAL UNIVERSITY (CN) | 2019-10-22 | — | — | US | disclosed |
| US-20180141964-A1 | FUNCTIONALIZED CYANOSILANE AND SYNTHESIS METHOD AND USE THEREOF | EAST CHINA NORMAL UNIVERSITY (CN) | 2018-05-24 | — | — | US | disclosed |
| US-20180141964-A1 | FUNCTIONALIZED CYANOSILANE AND SYNTHESIS METHOD AND USE THEREOF | EAST CHINA NORMAL UNIVERSITY (CN) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141964-A1 | FUNCTIONALIZED CYANOSILANE AND SYNTHESIS METHOD AND USE THEREOF | NCLN, PNN, MB | CYP2D6 4035/4885DRD2 2601/4885DRD4 2341/4885 |
| US-10450331-B2 | Functionalized cyanosilane and synthesis method and use thereof | NCLN, PNN, MB | CYP2D6 4035/4885DRD2 2601/4885DRD4 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.